Literature DB >> 9537934

Biological and virologic characteristics of primary HIV infection.

T W Schacker1, J P Hughes, T Shea, R W Coombs, L Corey.   

Abstract

BACKGROUND: The clinical events surrounding acute HIV-1 infection have been well described, but little is known about whether the virologic course of acute HIV-1 infection influences the subsequent progression of disease.
OBJECTIVE: To define the virologic natural history of acute and very early HIV infection.
DESIGN: Prospective, longitudinal cohort study.
SETTING: University of Washington Research Clinic PARTICIPANTS: 74 adults enrolled soon after acquisition of HIV (mean, 69 days). MEASUREMENTS: Plasma HIV-1 RNA levels; quantitative cell cultures; CD4 cell counts; and detailed clinical assessments done at study entry, biweekly for 1 month, monthly for 2 months, and quarterly thereafter.
RESULTS: In the first 30 days after acquisition of HIV, HIV-1 RNA levels varied greatly among participants (range, 27,200 to 1.6 x 10(6) copies per mL of plasma). Levels of HIV-1 RNA decreased by a mean of 6.5% per week for the first 120 days and then increased by a mean of 0.15% per week. CD4 cell counts decreased by a mean of 5.2 cells/mm3 per week for the first 160 days and by a mean of 1.9 cells/mm3 per week thereafter (P < 0.01). Disease progressed faster in participants who sought medical care for their acute seroconversion syndrome (P = 0.01) and those who had high plasma HIV-1 RNA levels 120 to 365 days after acquisition (P < 0.01). Peak levels in the first 120 days were not predictive of disease progression.
CONCLUSIONS: The variability in viral RNA levels associated with acute HIV-1 infection is greater than previously appreciated. Within 120 days of acquisition, plasma HIV RNA levels rapidly decrease to an inflection point, after which they gradually increase. Virus-host interactions soon after acquisition seem to have a major influence on the long-term outcome of HIV-1 disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9537934     DOI: 10.7326/0003-4819-128-8-199804150-00001

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  88 in total

1.  Evaluation of the quantiplex human immunodeficiency virus type 1 RNA 3.0 assay in a tertiary-care center.

Authors:  H Gale
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

2.  Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

Authors:  S I Staprans; P J Dailey; A Rosenthal; C Horton; R M Grant; N Lerche; M B Feinberg
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Simian-human immunodeficiency virus containing a human immunodeficiency virus type 1 subtype-E envelope gene: persistent infection, CD4(+) T-cell depletion, and mucosal membrane transmission in macaques.

Authors:  S Himathongkham; N S Halpin; J Li; M W Stout; C J Miller; P A Luciw
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection.

Authors:  Elizabeth Connick; Ronald J Bosch; Evgenia Aga; Rick Schlichtemeier; Lisa M Demeter; Paul Volberding
Journal:  J Acquir Immune Defic Syndr       Date:  2011-09-01       Impact factor: 3.731

5.  Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments.

Authors:  David C Nickle; Mark A Jensen; Daniel Shriner; Scott J Brodie; Lisa M Frenkel; John E Mittler; James I Mullins
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

6.  Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failure.

Authors:  Ingrid A Beck; Minyoung Jang; Jennifer McKernan-Mullin; Marta Bull; Thor Wagner; Sharon Huang; Lin-Ye Song; Sharon Nachman; Paul Krogstad; Susan H Eshleman; Andrew Wiznia; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2012-01-27       Impact factor: 2.205

7.  Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.

Authors:  H Nina Kim; Jing Wang; James Hughes; Robert Coombs; Jorge Sanchez; Stewart Reid; Sinead Delany-Moretlwe; Frances Cowan; Jonathan Fuchs; Susan H Eshleman; Leila Khaki; Moira A McMahon; Robert F Siliciano; Anna Wald; Connie Celum
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

8.  No Time to Delay! Fiebig Stages and Referral in Acute HIV infection: Seattle Primary Infection Program Experience.

Authors:  Joanne D Stekler; Kenneth Tapia; Janine Maenza; Claire E Stevens; George A Ure; Joshua D O'Neal; Aric Lane; James I Mullins; Robert W Coombs; Sarah Holte; Ann C Collier
Journal:  AIDS Res Hum Retroviruses       Date:  2018-06-13       Impact factor: 2.205

9.  Early control of highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys usually results in long-lasting asymptomatic clinical outcomes.

Authors:  Tatsuhiko Igarashi; Yasuyuki Endo; Yoshiaki Nishimura; Charles Buckler; Reza Sadjadpour; Olivia K Donau; Marie-Jeanne Dumaurier; Ronald J Plishka; Alicia Buckler-White; Malcolm A Martin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection.

Authors:  Erica Weber; Erin E Morgan; Jennifer E Iudicello; Kaitlin Blackstone; Igor Grant; Ronald J Ellis; Scott L Letendre; Susan Little; Sheldon Morris; Davey M Smith; David J Moore; Steven Paul Woods
Journal:  J Neurovirol       Date:  2012-12-19       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.